Cytokinetics CYTK
NASDAQ CYTK
$63.79 -0.16 (-0.24%)
As of: Oct 21, 2026 · 11:20 AM EDT

Cytokinetics (CYTK) Cash from Restructuring (2012)

Updated

Analysis

Cytokinetics (CYTK) Cash from Restructuring (2012) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,131.67 Bn 1,100.26 Bn 19.71 Bn
2 Johnson & Johnson 614.28 Bn 532.81 Bn 17.26 Bn
3 AbbVie 503.23 Bn 476.34 Bn 12.70 Bn
4 Merck 368.28 Bn 322.66 Bn 12.21 Bn
5 Novartis Ag 298.22 Bn 262.21 Bn 11.24 Bn
6 Astrazeneca 261.55 Bn 235.23 Bn 12.86 Bn
7 Amgen 235.92 Bn 191.31 Bn 7.24 Bn
8 Gilead Sciences 190.78 Bn 164.98 Bn 6.22 Bn
9 Pfizer 169.66 Bn 116.31 Bn 10.94 Bn
10 Cytokinetics 8.43 Bn 4.60 Bn 25.89 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 -112,000.00
Sep 30, 2012 110,000.00
Jun 30, 2012 -13,000.00
Mar 31, 2012 -41,000.00
API Access

Cytokinetics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=CYTK&period=max&api_key=YOUR_API_KEY